Topotecan oral - Athenex

Drug Profile

Topotecan oral - Athenex

Alternative Names: Oratopo

Latest Information Update: 31 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Athenex
  • Developer Athenex; Hong Kong Polytechnic University; McGill University
  • Class Antineoplastics; Camptothecins; Small molecules
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 31 Mar 2017 Preclinical trials in Cancer in Hong Kong (PO) before March 2017 (Athenex Pipeline, March 2017)
  • 28 Mar 2017 Preclinical trials in Cancer in USA (PO) before March 2017 (9213637; Athenex Pipeline, March 2017)
  • 28 Mar 2017 The US FDA approves IND application for topotecan oral in Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top